DBV Technologies SA
XMUN:DBV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
D
|
DBV Technologies SA
XMUN:DBV
|
FR |
|
C
|
Chefs' Warehouse Inc
XBER:2CF
|
US |
|
Harvey Norman Holdings Ltd
OTC:HNORF
|
AU |
|
Galapagos NV
F:GXE
|
BE |
|
Nongfu Spring Co Ltd
F:7NF
|
CN |
|
Toyo Tire Corp
F:TYR
|
JP |
|
B
|
Brambles Ltd
OTC:BMBLF
|
AU |
|
R
|
RWE AG
SWB:RWE
|
DE |
|
Zurich Insurance Group AG
OTC:ZFSVF
|
CH |
|
E
|
Eles Semiconductor Equipment SpA
MIL:ELES
|
IT |
|
3
|
3i Group PLC
F:IGQ5
|
UK |
|
Eni SpA
MIL:ENI
|
IT |
DBV Technologies SA
DBV Technologies is a biopharmaceutical company that develops skin patches for treating food allergies. Its main product idea is a patch called Viaskin, which delivers tiny amounts of an allergen through the skin to help train the immune system to react less strongly over time. The company focuses on allergies such as peanut and milk, where patients often need long-term management rather than a one-time cure. Its main customers are doctors, allergy specialists, hospitals, and eventually patients and caregivers if the therapy wins approval and reaches the market. DBV does not sell a broad range of medicines; it is built around a small number of allergy treatments in development. That makes the business more focused than a typical drug company, because the whole company depends on getting this patch technology approved and adopted. DBV would make money by selling prescription treatments and, in some cases, by working with partners that help develop or commercialize its products. Its role in the industry is different because it is trying to treat allergies through the skin rather than by injecting drugs or asking patients to avoid the allergen alone. In simple terms, it is a research-driven company turning one delivery method into a possible new treatment category for food allergy care.
DBV Technologies is a biopharmaceutical company that develops skin patches for treating food allergies. Its main product idea is a patch called Viaskin, which delivers tiny amounts of an allergen through the skin to help train the immune system to react less strongly over time. The company focuses on allergies such as peanut and milk, where patients often need long-term management rather than a one-time cure.
Its main customers are doctors, allergy specialists, hospitals, and eventually patients and caregivers if the therapy wins approval and reaches the market. DBV does not sell a broad range of medicines; it is built around a small number of allergy treatments in development. That makes the business more focused than a typical drug company, because the whole company depends on getting this patch technology approved and adopted.
DBV would make money by selling prescription treatments and, in some cases, by working with partners that help develop or commercialize its products. Its role in the industry is different because it is trying to treat allergies through the skin rather than by injecting drugs or asking patients to avoid the allergen alone. In simple terms, it is a research-driven company turning one delivery method into a possible new treatment category for food allergy care.
VITESSE Trial Progress: Enrollment in the key VITESSE Phase III trial for Viaskin Peanut in children ages 4–7 remains on track, with final screening expected by end of Q3 2024.
Regulatory Dialogue: Ongoing discussions with the FDA continue regarding the COMFORT Toddlers safety study protocol and proposed product labeling, with DBV awaiting agency feedback.
Cash Runway Extended: Cost-saving measures have extended the company’s cash runway into Q1 2025, beyond the previous year-end 2024 guidance.
Financial Performance: Operating expenses increased due to clinical activity and nonrecurring costs, leading to a net loss of $60.5 million for the first half.
Upcoming Milestones: Key expected milestones include VITESSE enrollment completion, FDA feedback on toddler studies and labeling, and year 3 results from the EPITOPE trial.
